Literature DB >> 9667403

Cardiac tamponade due to systemic lupus erythematosus in a 7-year-old boy with selective IgG subclass deficiency.

A Tamura1, K Agematsu, R Urasawa, K Naganuma, A Komiyama.   

Abstract

UNLABELLED: Systemic lupus erythematosus (SLE) was observed in a 7-year-old boy with IgG2 and IgG4 subclass deficiencies who had been treated with immunoglobulin (100-200 mg/kg/4 weeks) since 2 years of age. The mother and the half-brother displayed the same deficiency. Serum IgG mainly consisted of IgG1 (98.9%) during the acute phase of SLE due to transient IgG3 deficiency. While he had no common manifestations of SLE such as arthritis or nephropathy, he developed cardiac tamponade due to massive pericardial effusion.
CONCLUSION: The clinical features of SLE in the present case such as the development of cardiac tamponade and the absence of renal involvement may result from the markedly imbalanced IgG subclass distribution among auto-antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667403     DOI: 10.1007/s004310050857

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  3 in total

1.  Chronic glomerulonephritis associated with IgG subclass deficiency.

Authors:  Koichi Kamei; Atsuko Nakagawa; Yasufumi Otsuka; Makiko Nakayama; Shinichi Kobayashi; Kentaro Matsuoka; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2007-04-17       Impact factor: 3.714

2.  Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort.

Authors:  Joo-Hee Kim; Han-Jung Park; Gil-Soon Choi; Jeong-Eun Kim; Young-Min Ye; Dong-Ho Nahm; Hae-Sim Park
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

3.  Pediatric systemic lupus erythematosus patients in South Africa have high prevalence and severity of cardiac and vascular manifestations.

Authors:  Michael J Harrison; Liesl J Zühlke; Laura B Lewandowski; Christiaan Scott
Journal:  Pediatr Rheumatol Online J       Date:  2019-11-26       Impact factor: 3.054

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.